Amneal Pharmaceuticals
AMRX
165 hedge funds and large institutions have $1.6B invested in Amneal Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 165 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
32.68% more ownership
Funds ownership: 0% → 32.68% (+33%)
68% less call options, than puts
Call options by funds: $336K | Put options by funds: $1.06M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FI
Fosun International
Hong Kong,
China
|
+$356M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$191M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$153M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$139M |
| 5 |
BlackRock
New York
|
+$102M |
Top Sellers
AMRX Hedge Fund Activity: Q2 2018 in Review
165 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q2 2018, worth a combined $1.6B.
Buyers outnumbered sellers: 165 funds opened new AMRX positions and 0 closed out — a net gain of 165 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fosun International, opening a new position worth an estimated $356M.
- 165 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q2 2018, up from 0 in Q1 2018.
- Funds reported $1.6B of Amneal Pharmaceuticals stock for Q2 2018.
- 165 funds opened new Amneal Pharmaceuticals positions in Q2 2018 and 0 closed out, a net change of +165 holders.
- The largest Amneal Pharmaceuticals buyer in Q2 2018 was Fosun International, an estimated $356M added.
Based on aggregated 13F filings for Q2 2018.